
Axcella Health AXLA
Quartalsbericht 2023-Q2
hinzugefügt 03.08.2023
Axcella Health Langfristiger Schuldenstrom 2011-2026 | AXLA
Langfristiger Schuldenstrom Jährlich Axcella Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.59 M | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.59 M | 1.59 M | 1.59 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Ascendis Pharma A/S
ASND
|
14.2 M | $ 219.68 | 1.92 % | $ 5 B | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Seres Therapeutics
MCRB
|
6.68 M | $ 8.28 | - | $ 1.06 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 19.45 | 1.14 % | $ 909 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Mesoblast Limited
MESO
|
3.19 M | $ 15.44 | 7.82 % | $ 10 B | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | ||
|
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
440 K | $ 0.67 | -5.25 % | $ 7.67 M | ||
|
Mirum Pharmaceuticals
MIRM
|
2.14 M | $ 90.39 | 2.86 % | $ 4.54 B | ||
|
Autolus Therapeutics plc
AUTL
|
5.05 M | $ 1.34 | 1.52 % | $ 342 M | ||
|
MediciNova
MNOV
|
194 K | $ 1.45 | - | $ 71.1 M | ||
|
CytomX Therapeutics
CTMX
|
4.24 M | $ 4.37 | 2.95 % | $ 603 M | ||
|
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
137 K | $ 2.69 | 1.37 % | $ 16.9 M | ||
|
Dynavax Technologies Corporation
DVAX
|
4.18 M | - | - | $ 2.02 B | ||
|
Enochian Biosciences
ENOB
|
313 K | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Merck & Co.
MRK
|
294 M | $ 117.56 | 1.02 % | $ 294 B | ||
|
Marker Therapeutics
MRKR
|
577 K | $ 1.37 | 8.73 % | $ 21 M | ||
|
Moderna
MRNA
|
17 M | $ 53.09 | 3.41 % | $ 20.7 B | ||
|
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | ||
|
Arbutus Biopharma Corporation
ABUS
|
547 K | $ 4.47 | 3.71 % | $ 856 M | ||
|
Homology Medicines
FIXX
|
693 K | - | 0.77 % | $ 53.4 M |